Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.
We currently have 22 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.6 billion (IQVIA, June 2018).
We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.
"As we execute our strategy, our focus is to scale up and strengthen our business, so we can deliver sustained financial performance."
Teligent, Inc. to Present at the Raymond James Life Sciences and MedTech Conference on June 19th 2019
BUENA, N.J. , June 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic phar...Learn More
Teligent, Inc. Announces First Quarter 2019 Results
BUENA, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic phar...Learn More
Teligent, Inc. to Hold Conference Call for First Quarter 2019 Results on Monday May 6th, 2019
BUENA, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharm...Learn More